AI-based Antibody Therapeutics Developability Assessment and Its Engineering

Monoclonal antibodies (mAbs) have become essential in treating a wide spectrum of diseases, with over 100 therapeutic antibody products now approved and commercially available. Although mAbs represent the fastest-growing sector in therapeutics, their development is complex, with developability being a crucial consideration. Developability evaluates the potential of an antibody candidate to be produced as a safe and effective drug.

In the context of Contract Research and Manufacturing Organizations (CRMOs), the developability assessment focuses on ensuring that an antibody candidate can progress through the chemistry, manufacturing, and control (CMC) processes efficiently, affordably, and within an acceptable timeframe. It’s important to examine and refine the properties related to developability early on, ideally during the discovery phase, to reduce the chances of advancing an antibody with limited developability to the CMC stage. Artificial intelligence is transforming bioinformatics research and its applications, particularly in protein and antibody analysis. AI methods are now being employed to improve the developability screening and optimization of antibody candidates.

In this webinar, we are excited to present our Immunoinformatics Comprehensive Service Platform, which leverages AI for the developability assessment of antibody therapeutics. This covers assessments of immunogenicity, viscosity, aggregation, degradation, and post-translational modifications (PTMs). We will also cover our antibody engineering services, including humanization, caninization, felinization, and optimizing expression. Case studies will be presented to demonstrate our capabilities in assessing developability and performing antibody engineering. The webinar will end with a Q&A session, allowing participants to delve into any specific areas of interest regarding AI in antibody development.

Join us to learn how our AI-based platform can facilitate the development process for antibody therapeutics, ensuring candidates are not only therapeutically effective but also viable for large-scale production and clinical use.

In this webinar, you will learn about:

Importance and Challenges of Developability in Antibody Therapeutics

Role of AI in Transforming Developability Assessment

GenScript’s Solutions for Antibody Developability Assessment and Engineering

In this webinar, you will learn

Webinar Details

  • Date: June 21st, 2024
  • Time: 10:00 am EDT (NA) / 3:00 pm BST (UK) / 4:00 pm CEST (EU-Central)
  • Speaker:
Dr. Carter Hao Dr. Carter Hao

Senior Bioinformatics Scientist, GenScript

Carter Hao received his PhD degree in Control Science and Engineering from Zhejiang University of Technology. He is now a Bioinformatics Senior Scientist at GenScript Co. Ltd. and mainly takes charge of the research and development of antibody-related applications. His research interests include protein structure prediction, antibody developability prediction (viscosity, immunogenicity, aggregation, stability, etc.), antibody binding affinity maturation, antibody humanization, caninization, felinization, and evolution computation. He has published 20+ papers in international journals in the above research fields, including the European Journal of Pharmaceutical Sciences, IEEE TCBB, Information Science, etc.

Speaker-related Webinars


Do you like the current new website?